IL17A and psoriatic arthritis: Bimekizumab (146–148) can effectively and selectively inhibit IL-17A and IL-17F, being currently in the phase III clinical trial stage for the treatment of various inflammatory diseases, including plaque psoriasis, psoriatic arthritis.